AI Stock Analysis: Is It Time to Invest in PFE?

July 9, 8:52 am

Pfizer Inc. is a global pharmaceutical corporation with over a century of experience in the healthcare sector, providing a wide array of healthcare solutions, including pharmaceuticals and vaccines. The company is renowned for its research and development prowess, which has led to the creation of life-saving drugs and treatments over the years. Its portfolio covers major therapeutic areas, ranging from oncology and immunology to cardiology and neuroscience.

Price & AI Score for PFE.

Fundamental Analysis

Pfizer reported revenue for the last quarter at $14.9B, reflecting an increase of 4.42% compared to the previous quarter, signaling a positive short-term growth trend. However, this figure is down 19.51% compared to the same quarter last year, potentially indicating waning demand or increased competition in certain sectors.

Net income for the last quarter was $3.12B, a substantial increase of 192.46% compared to the quarter before, suggesting robust profitability improvements. Yet, this is a decrease of 43.80% compared to the same quarter last year, presenting some signs of profitability concerns.

The EBITDA for the last quarter stood at $5.5B, increasing dramatically by 341.56% compared to the preceding quarter but witnessing a drop of 30.13% when juxtaposed with the same quarter last year. This mixed bag of data points reflects both short-term financial strength and longer-term potential issues.

The current Price-to-Earnings (P/E) ratio sits at 69.24. This relatively high figure may imply overvaluation, indicating that investors are paying a premium for future earnings growth, which could pose a bearish outlook if not substantiated by substantial earnings growth.

Technical Analysis

The current stock price of Pfizer is $27.37. This represents a decrease of 4.23% compared to a month ago, raising short-term concerns. Over the past year, the stock price has decreased by 18.95%, raising longer-term concerns about the company's valuation.

The trend appears bearish with a 10-day Simple Moving Average (SMA10) of 27.89, slightly lower than the previous SMA10 of 27.95. The Relative Strength Index (RSI) is 82.6, suggesting the stock is potentially in an overbought condition, which often precedes a price decline.

Alternative Data Analysis

Evaluating job postings and employee sentiment, Pfizer has 824 open positions. This number has been stable over the last few months, indicating a steady operational status. However, the business outlook has decreased by 6% over the past few months, which might indicate a less optimistic view for future performance.

Customer acquisition metrics reveal an estimated 1.7M visitors to Pfizer's webpage, down by 7% in recent months, which could denote a potential loss in customer interest or engagement. On social media, Pfizer has 120,000 followers on Instagram and 490,000 followers on Twitter, with both metrics remaining unchanged, indicating stagnant social engagement.

According to the AltIndex AI score, which combines fundamental, technical, and alternative data analyses, Pfizer has a score of 41, suggesting a "Hold" recommendation.


Based on a comprehensive analysis of Pfizer's current financial health, market performance, and alternative data metrics, several factors warrant consideration. Though there are short-term gains in revenue, net income, and EBITDA, the long-term comparison with the previous year indicates a declining trend. The high P/E ratio suggests potential overvaluation and the bearish technical indicators caution against immediate optimism.

On the alternative data front, while Pfizer remains stable in job postings and social media presence, decreases in business outlook and webpage visitors could reflect potential future challenges.

Given the mixed signals from the different analyses and the conservative AI score recommendation, it might be prudent for investors to maintain a "Hold" position on Pfizer stock. Watching for further developments in earnings reports and broader market conditions will be essential for making an informed decision.

Disclaimer: This article, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current. Visit PFE AI Stock Analysis for a more up-to-date analysis.

Get More Insights

Sign up and get access to a personalized dashboard, deeper insights, AI stock picks, stock alerts, weekly newsletter and much more.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.